Av
Astra Zeneca meddelade i dag, tisdag, att utvecklingsprogrammet för läkemedelskandidaten olaparib avbryts. Olaparib utvecklas för behandling av äggstockscancer i klinisk fas II men då bolaget utvärderade interimsresultatet såg de att preparatet inte gav önskvärd effekt i total överlevnad. Bolaget har dessutom försökt att hitta en lämplig dos för att kunna testa preparatet i kliniska fas III-studier, men inte lyckats med det. Astra Zeneca har därför beslutat att lägga utvecklingsprojektet på is.
Det ser även mörkt ut för Astra Zenecas läkemedelskandidat TC-5214, för behandling av depression, som utvecklas i ett fas III-program. Läkemedelskandidaten misslyckades med att uppnå det primära effektmåttet i den första av programmets totalt fyra kliniska studier. Nu meddelar bolaget att kandidaten inte heller uppnår effekten den andra kliniska studien.
De två bakslagen innebär att Astra Zeneca nu gör en nedskrivning på totalt 381,5 miljoner amerikanska dollar före skatt, motsvarande 2,6 miljarder svenska kronor, under det fjärde kvartalet 2011. 285 miljoner amerikanska dollar, motsvarande 1,9 miljoner kronor, skrivs ned till följd av att utvecklingsprogrammet med olaparib läggs ned. Den resterande delen på 96,5 miljoner amerikanska dollar, motsvarande 667 miljoner kronor, skrivs ned eftersom en positiv utgång för de två pågående fas III-studierna med TC-5214 inte längre är lika sannolik. Astra Zeneca har tidigare planerat att lämna in registreringsansökan till det amerikanska läkemedelsverket för det antidepressiva preparatet till det andra halvåret under 2012 men kommer nu att se över planerna.
Trots nedskrivningarna tror Astra Zeneca att den tidigare prognosen för vinst per aktie kommer att stå fast. Dock tror de att vinsten landar i den lägre delen av det förutspådda intervallet mellan 7,20 och 7,40 dollar per aktie.
Det ser även mörkt ut för Astra Zenecas läkemedelskandidat TC-5214, för behandling av depression, som utvecklas i ett fas III-program. Läkemedelskandidaten misslyckades med att uppnå det primära effektmåttet i den första av programmets totalt fyra kliniska studier. Nu meddelar bolaget att kandidaten inte heller uppnår effekten den andra kliniska studien.
De två bakslagen innebär att Astra Zeneca nu gör en nedskrivning på totalt 381,5 miljoner amerikanska dollar före skatt, motsvarande 2,6 miljarder svenska kronor, under det fjärde kvartalet 2011. 285 miljoner amerikanska dollar, motsvarande 1,9 miljoner kronor, skrivs ned till följd av att utvecklingsprogrammet med olaparib läggs ned. Den resterande delen på 96,5 miljoner amerikanska dollar, motsvarande 667 miljoner kronor, skrivs ned eftersom en positiv utgång för de två pågående fas III-studierna med TC-5214 inte längre är lika sannolik. Astra Zeneca har tidigare planerat att lämna in registreringsansökan till det amerikanska läkemedelsverket för det antidepressiva preparatet till det andra halvåret under 2012 men kommer nu att se över planerna.
Trots nedskrivningarna tror Astra Zeneca att den tidigare prognosen för vinst per aktie kommer att stå fast. Dock tror de att vinsten landar i den lägre delen av det förutspådda intervallet mellan 7,20 och 7,40 dollar per aktie.
"To supply Swedish and Danish laboratories with laboratory equipment and furniture of highest quality and offer service on all delivered products." 
"Our products enable an increased number of transplants leading to substantial cost savings for society and increased quality of life for patients." 
"TFS is today the leading European development partner for biopharmaceutical companies in their global clinical development process." 
"Best in class companies see the value of optimising their business by having an effective strategy for information management and documentation." 
"We are entirely devoted to luminescence technology." 
"To adapt Competent Authorities´ requirements into opportunities is not just an artform - today it´s a business necessity." 
"Your global partner of pharmaceutical service and cGMP manufacturing" 
"Our goal is to invest in innovations and develop new unique pharmaceuticals" 
"We turn medical research into applications for better health and well-being." 
"Mercodia has been a supplier of reliable assays since 1991" 
"VWR is a global laboratory distributor of chemicals, life science products, consumables, equipment, instruments, furniture, e-commerce and services" 
"Dilafor is developing new products in the field of obstetrics, to provide an effective solution to the challenge of dystocia or protracted labor"
" 
"We offer effective staffing solutions provided by specialists, we understand a company’s specific needs and we know where to find the best talent." 
"Together with Zacco our clients achieve their business goals through the management of their intellectual property." 
"We promise to go the extra mile every day to ensure you receive the highest level of service and value with each shipment you entrust to us." 
"PCG - a professional full service CRO for your clinical trials.
Powered by Viedoc, globally trusted eCRF, keeping trials within budget and timelines" 
"With our first class products and our committed and skilled colleagues we guarantee our customers the best support in the market, at no extra charge." 
"Our organisation value is to contribute to positioning Scandinavian healthcare and research in absolute world class." 
"To become an internationally leading dental company with innovative, proprietary products of high therapeutic and commercial value." 
"Our services in ligand-based and structure-based drug design is a cost-efficient alternative for smaller pharmaceutical companies" 
"Our vision is to become one of the top 10 global providers of scientific instruments; we will get there by striving for market leadership in our respective product and application niches."
" 
"We are making it more attractive for companies to invest in innovation with reduced corporation tax on profits from patents to 10%." 
"APL provides high-quality services to Life Science. We are a Dedicated Partner from Discovery to Market." 
"We are recognized as a flexible partner with short decision and lead times plus a proven record for the highest quality and cost efficiency." 
"Uppsala BIO is a life science pathfinder. We build ways to make life science flourish, in cooperation with industry, academia, society and healthcare." 
"Our aim is to be the best drug development partner to the biotechnology and pharmaceutical industry no matter where you are based." 
"We aim to be the pioneering benchmark in user-friendly software experience in combination with the highest level of quality." 
"We help our clients create significant business value through scientific expertise." 
"Discover your possibilities in one of Europe´s most productive life science regions. Welcome to Stockholm-Uppsala."
" 
"To be the most attractive node and business platform in the Nordic countries for new and innovative Life Science companies" 
"Novel products for CVD treatment and prevention." 
"Innovation takes place when biology meets engineering; ICT is an enabler to solve the needs for increased functionality and reduced cost in Life Science" 
"Medivir is a specialty pharmaceutical company with unique positioning on the Nordic market and our goal is become a profitable company in high growth" 
"To be acknowledged as the Best-in-Class provider of pharmaceutical development and manufacturing services by customers, employees & other stakeholders" 
"Anton Paar is a product and service leader in the field of scientific instruments. We deliver uncompromised quality in everything we do." 
"Your work is important to us, we are committed to your success.
Innovative tools? Please download the Promega app." 
"As a full service CRO with offices in all Nordic countries we can provide our customer with professional support throughout the clinical research." 
"Our reliability, customer service, global network and integrated technology make World Courier service truly "A service no one else can deliver"." 
"We have a unique technological platform, built around 5HT-receptor antagonism, for the treatment of inflammation and pain"." 
"The PolyPeptide Group is a world class manufacturer of peptide active pharmaceutical ingredients." 
"Allenex is a life science company that develops, manufactures, markets and sells high quality products for the transplantation market." 
"To develop innovative and effective pharmaceuticals within autoimmune/ inflammatory diseases and cancer where major medical need exists" 
